Rapport Therapeutics, Inc. Common Stock
(RAPP - NASDAQ)
35,40 USD
📋 Profilo Aziendale

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.

|